Long-term Efficacy of Drug-coated Balloon Versus Drug-eluting Stent in Large de Novo Coronary Lesions

Inclusion Criteria: 1. Age ≥18 years and ≤80 years, regardless of gender; 2. De novo lesion in a native coronary artery; 3. Stable angina, or unstable angina, or old myocardial infarction or asymptomatic myocardial ischemia; 4. Reference vessel diameter is 2.75mm-4.0mm with diameter stenosis ≥70% or ≥50% (with evidence of ischemia) and TIMI flow ≥1; 5. The subject can receive any type of coronary vascular revascularization (including balloon angioplasty, stent implantation or coronary artery bypass grafting); 6. The subject who can understand the purpose of the trial, voluntarily participate in and sign an informed consent form, and is willing to accept clinical follow-up. Exclusion Criteria: 1. Reference vessel diameter \<2.75 mm or \>4.0 mm; 2. In stent restenosis; 3. Left main lesion, chronic complete occlusion lesion; 4. Ostial lesion ≤2mm from the LM, or bifurcation lesion with branch vessel diameter≥2.5mm; 5. There is a large scale of thrombus in the target vessel, and the thrombus grade \>3 after thrombolysis or aspiration; 6. Severe heart failure (NYHA IV); 7. Severe renal failure (GFR\<30ml/min) or undergoing hemodialysis treatment; 8. Severe liver failure (bilirubin is over 2 times the upper limit of normal, or alanine aminotransferase is over 3 times the upper limit of normal); 9. Patients with vein graft restenosis after bypass or severe heart valve disease; 10. Pregnant or breastfeeding female patients; 11. The life expectancy of the patient is less than 12 months; 12. The subject cannot be treated with anticoagulation because of bleeding tendency, history of active peptic ulcer, stroke in the 6 months before surgery, anti-platelet agents or anticoagulant treatment contraindications; 13. Anemia (women's hemoglobin \<117g/L, or men's hemoglobin \<134g/L), or thrombocytopenia detected before the intervention within 6 months (\<100×10⁹/L); 14. Planned to perform non-cardiac surgery within 12 months after index procedure; 15. The subject who participated in other clinical trials of drugs or instruments and did not reach time of primary endpoint; 16. Heart transplant patients; 17. Allergic to aspirin, clopidogrel, heparin, contrast agents, or paclitaxel; 18. The investigator judged that the patient had poor compliance and could not complete the study as required.